Oramed Pharmaceuticals (ORMP) to Release Quarterly Earnings on Thursday

Oramed Pharmaceuticals (NASDAQ:ORMP) will likely be issuing its results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

Oramed Pharmaceuticals Stock Up 1.7%

Shares of NASDAQ ORMP opened at $3.55 on Tuesday. Oramed Pharmaceuticals has a 52 week low of $1.82 and a 52 week high of $3.76. The business’s 50 day moving average price is $3.42 and its 200 day moving average price is $2.89. The firm has a market cap of $141.30 million, a P/E ratio of 2.82 and a beta of 1.31.

Oramed Pharmaceuticals Dividend Announcement

The firm also recently disclosed a dividend, which was paid on Monday, January 26th. Stockholders of record on Friday, January 16th were issued a $0.25 dividend. The ex-dividend date of this dividend was Friday, January 16th. Oramed Pharmaceuticals’s dividend payout ratio is 19.84%.

Institutional Trading of Oramed Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Marshall Wace LLP purchased a new position in Oramed Pharmaceuticals during the fourth quarter valued at approximately $738,000. HRT Financial LP purchased a new stake in Oramed Pharmaceuticals in the 4th quarter worth approximately $131,000. Quadrature Capital Ltd acquired a new stake in shares of Oramed Pharmaceuticals during the 4th quarter worth approximately $119,000. Squarepoint Ops LLC grew its stake in shares of Oramed Pharmaceuticals by 95.1% during the 4th quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 28,406 shares during the period. Finally, Jane Street Group LLC increased its holdings in shares of Oramed Pharmaceuticals by 31.2% during the 4th quarter. Jane Street Group LLC now owns 78,259 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 18,600 shares in the last quarter. Hedge funds and other institutional investors own 12.73% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of Oramed Pharmaceuticals in a research note on Monday, December 29th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company has a consensus rating of “Hold”.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.